[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612082":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":48,"centralContacts":53,"locations":59,"responsibleParty":150,"collaborators":29,"id":153,"slug":154,"hasResults":155,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":29,"eligibilityCriteria":159,"healthyVolunteers":155,"sex":160,"minAge":161,"maxAge":162,"enrollmentInfo":163,"targetDuration":29,"studyType":166,"phases":167,"briefSummary":169,"conditions":170,"keywords":172,"overallStatus":116,"whyStopped":29,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":180,"completionDateStruct":181,"leadSponsor":183,"locationsCount":184},{"fullName":5,"class":6},"Eye & ENT Hospital of Fudan University","OTHER",[8,17],{"label":9,"type":10,"description":11,"interventionNames":12},"neoadjuvant therapy followed by surgery and (C)RT group","EXPERIMENTAL","Patients initially receive immunotherapy with Finolizumab and chemotherapy with albumin-bound paclitaxel and cisplatin. Patients with response of complete reaction (CR)\u002Fpartial reaction (PR)≥50% after neoadjuvant chemotherapy then receive surgery, followed by postoperative radiotherapy or chemoradiotherapy.",[13,14,15,16],"Drug: Finolizumab","Drug: Albumin-Bound Paclitaxel \u002Fnab-Paclitaxel","Drug: Cisplatin","Procedure: Surgery with postoperative radiotherapy or chemoradiotherapy.",{"label":18,"type":19,"description":20,"interventionNames":21},"neoadjuvant therapy followed by CCRT group","ACTIVE_COMPARATOR","Patients initially receive immunotherapy with Finolizumab and chemotherapy with albumin-bound paclitaxel and cisplatin. Patients with response of complete reaction (CR)\u002Fpartial reaction (PR)≥50% after neoadjuvant chemotherapy then receive definitive radiotherapy with concurrent cisplatin-based chemotherapy.",[13,14,15,22],"Radiation: Definitive radiotherapy",[24,30,34,38,43],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"DRUG","Finolizumab","200mg every 3 weeks (q3w) for 2 cycles.",[18,9],null,{"type":25,"name":31,"description":32,"armGroupLabels":33,"otherNames":29},"Albumin-Bound Paclitaxel \u002Fnab-Paclitaxel","260mg\u002Fm², day 1, every 3 weeks (q3w) for 2 cycles.",[18,9],{"type":25,"name":35,"description":36,"armGroupLabels":37,"otherNames":29},"Cisplatin","25mg\u002Fm², days 1-3, every 3 weeks (q3w) for 2 cycles.",[18,9],{"type":39,"name":40,"description":41,"armGroupLabels":42,"otherNames":29},"RADIATION","Definitive radiotherapy","Definitive radiotherapy (68-70Gy) with concurrent cisplatin-based chemotherapy (25mg\u002Fm², days 1-3, every 3 weeks)",[18],{"type":44,"name":45,"description":46,"armGroupLabels":47,"otherNames":29},"PROCEDURE","Surgery with postoperative radiotherapy or chemoradiotherapy.","surgery with postoperative radiotherapy or chemoradiotherapy.",[9],[49],{"name":50,"affiliation":51,"role":52},"Ming Zhang, PhD","Eye & ENT Hospital, Fudan University","PRINCIPAL_INVESTIGATOR",[54],{"name":55,"role":56,"phone":57,"phoneExt":29,"email":58},"Chiyao Hsueh","CONTACT","021-64377134","hsuehchiyao@gmail.com",[60,78,92,105,115,127,137],{"facility":61,"status":62,"city":63,"state":64,"zip":29,"country":65,"countryCode":66,"cosmosGeoPoint":67,"geoPoint":72,"contacts":73},"Harbin Medical University Cancer Hospital","NOT_YET_RECRUITING","Harbin","Heilongjiang","China","CN",{"type":68,"coordinates":69},"Point",[70,71],126.65,45.75,{"lat":71,"lon":70},[74],{"name":75,"role":56,"phone":76,"phoneExt":29,"email":77},"Susheng Miao, PhD","8613796620079","drmiaosusheng@126.com",{"facility":79,"status":62,"city":80,"state":81,"zip":29,"country":65,"countryCode":66,"cosmosGeoPoint":82,"geoPoint":86,"contacts":87},"Shandong Provincial ENT Hospital","Jinan","Shandong",{"type":68,"coordinates":83},[84,85],116.99722,36.66833,{"lat":85,"lon":84},[88],{"name":89,"role":56,"phone":90,"phoneExt":29,"email":91},"Zhenghua Lv, PhD","8615168889970","entlvzhenghua@163.com",{"facility":93,"status":62,"city":94,"state":29,"zip":29,"country":65,"countryCode":66,"cosmosGeoPoint":95,"geoPoint":99,"contacts":100},"Beijing Tongren Hospital, Capital Medical University","Beijing",{"type":68,"coordinates":96},[97,98],116.39723,39.9075,{"lat":98,"lon":97},[101],{"name":102,"role":56,"phone":103,"phoneExt":29,"email":104},"Qi Zhong, PhD","8613520298736","zhongqi_ent@126.com",{"facility":106,"status":62,"city":94,"state":29,"zip":29,"country":65,"countryCode":66,"cosmosGeoPoint":107,"geoPoint":109,"contacts":110},"Cancer Hospital Chinese Academy of Medical Sciences",{"type":68,"coordinates":108},[97,98],{"lat":98,"lon":97},[111],{"name":112,"role":56,"phone":113,"phoneExt":29,"email":114},"Changming An, PhD","8613811381160","mran1979@163.com",{"facility":51,"status":116,"city":117,"state":29,"zip":29,"country":65,"countryCode":66,"cosmosGeoPoint":118,"geoPoint":122,"contacts":123},"RECRUITING","Shanghai",{"type":68,"coordinates":119},[120,121],121.45806,31.22222,{"lat":121,"lon":120},[124],{"name":50,"role":56,"phone":125,"phoneExt":29,"email":126},"8621-64377151","zmzlm@163.com",{"facility":128,"status":62,"city":117,"state":29,"zip":29,"country":65,"countryCode":66,"cosmosGeoPoint":129,"geoPoint":131,"contacts":132},"Zhongshan Hospital of Fudan University",{"type":68,"coordinates":130},[120,121],{"lat":121,"lon":120},[133],{"name":134,"role":56,"phone":135,"phoneExt":29,"email":136},"Xinsheng Huang, PhD","8613681791739","huang.xinsheng@zs-hospital.sh.cn",{"facility":138,"status":62,"city":139,"state":29,"zip":29,"country":65,"countryCode":66,"cosmosGeoPoint":140,"geoPoint":144,"contacts":145},"Tianjin Medical University Cancer Institute & Hospital","Tianjin",{"type":68,"coordinates":141},[142,143],117.17667,39.14222,{"lat":143,"lon":142},[146],{"name":147,"role":56,"phone":148,"phoneExt":29,"email":149},"Xuan Zhou, PhD","8618622682591","xuanzhou@tmu.edu.cn",{"type":52,"investigatorFullName":151,"investigatorTitle":152,"investigatorAffiliation":5,"oldNameTitle":29,"oldOrganization":29},"Ming Zhang","Principal Investigator","100612082","phase-2-neoadjuvant-chemotherapy-combined-with-finotonlimab-in-the-treatment-of-locally-advanced-hypopharyngeal-carcinoma-100612082",false,"NCT07248956","Neoadjuvant Chemotherapy Combined With Finotonlimab in the Treatment of Locally Advanced Hypopharyngeal Carcinoma","Neoadjuvant Chemotherapy Combined With Finotonlimab in the Treatment of Locally Advanced Hypopharyngeal Carcinoma: A Multicenter Randomized Controlled Study","Inclusion Criteria:\n\n1. Willingness to provide written informed consent;\n2. Age ≥18 and ≤75 years;\n3. Treatment-naïve for malignant disease;\n4. Resectable stage III-IVA hypopharyngeal carcinoma with response of PR ≥ 50% after neoadjuvant therapy according to RECIST 1.1 ;\n5. ECOG performance status 0-2.\n\nExclusion Criteria:\n\n1. Pregnancy or breastfeeding status;\n2. Hypersensitivity to sintilimab, nab-paclitaxel, or their formulation components;\n3. Poorly controlled cardiovascular conditions or other diseases;\n4. Active or documented history of autoimmune diseases requiring systemic treatment;\n5. Synchronous or metachronous malignancies;\n6. Other conditions deemed ineligible for the study by investigators.","ALL","18 Years","75 Years",{"count":164,"type":165},116,"ESTIMATED","INTERVENTIONAL",[168],"PHASE2","This is a multi-center, randomized controlled, prospective clinical study.",[171],"Hypopharyngeal Carcinoma",[173,174,175],"PD-1 inhibitor","neoadjuvant therapy","locally advanced","2025-12-22",{"date":178,"type":179},"2025-12-23","ACTUAL",{"date":176,"type":179},{"date":182,"type":165},"2029-12-30",{"name":5,"class":6},7]